Portal de Periódicos da CAPES

Proceedings of the 7th Neurological Disorders Summit (NDS-2022)

2022; Volume: 08; Issue: 01 Linguagem: Inglês

10.17756/jnen.2022-suppl1

2469-407X

Jin Hyuck, Rebecca Grzadzinski, Alapika Jatkar, Mark D. Shen, Jessica B. Girault, Catherine A. Burrows, Isabella Stallwor- Thy, Steve Dager, Robert T. Schultz, Kelly N. Botteron, Martin Styner, Joseph Piven, Heather C. Hazlett, Christy Hom, Jordan P. Harp, Lisa Koehl, Kathryn L. Van Pelt, Eric Doran, Elizabeth Head, Ira T. Lott, Frederick A. Schmitt, Charles A. Williams, Shreya Pandey, Hariom Kumar Solanki, Nayanika Tummala, Sana Rehman, Kristýna Kárová, Lucia Machová Urdzíková, Pavla Jendelová, Jessica C. F. Kwok, James W. Fawcett,

Neurology and Historical Studies

Various amyloidogenic proteins have been suggested to be involved in the onset and progression of neurodegenerative diseases (ND) such as Alzheimer's disease (AD).Particularly, the aggregation of misfolded amyloid-β (Aβ) and hyperphosphorylated tau (pTau) are linked to the neurodegeneration and pathogenesis of AD.In order to care these diseases, multiple small molecules have been developed to regulate the aggregation pathways of these amyloid proteins.In addition to controlling the aggregation of amyloidogenic protiens, maintaining the levels of the proteins in the brain by amyloid degrading enzymes [ADE; neprilysin (NEP), insulin degrading enzyme (IDE), and matrix metalloproteinases (MMPs)] is also essential to cure AD.Therefore, numerous biological molecules and chemical agents have been investigated as either inducer or inhibitor against the levels and activities of ADE.Although the side effects of enhancing the activity of ADE could occur, the removal of amyloidogenic proteins could result in a relative good strategy to treat AD.Furthermore, since the causes of AD are diverse, various multi-functional (multitarget) chemical agents have been designed to control the actions of multiple risk factors of AD, including Aβ, metal ions, and/or reactive oxygen species (ROS).Many of them, however, were invented without considerations of regulating ADE levels and actions.Incorporation of previously created molecules targeting Aβ, metal ions, and/or ROS with the chemical agents handling ADE could be a promising way to treat AD.This presentation introduces the relationships between ADE and molecules capable of modulating the activity and expression of ADE.